Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL

A significantly lower percentage of patients receiving a 70-mg or 140-mg dose of erenumab had severe disability during treatment compared with placebo.

Source link

Related posts

Non-ataxic manifestations of Spinocerebellar ataxia-2, their determinants and predictors


Plasma from some patients with amyotrophic lateral sclerosis exhibits elevated formaldehyde levels


rehabathome: Types of Spinal Cord Injury (SCI) Typical…


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy